These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 30136603)

  • 21. Steady-state pharmacokinetics of lamotrigine when converting from a twice-daily immediate-release to a once-daily extended-release formulation in subjects with epilepsy (The COMPASS Study).
    Tompson DJ; Ali I; Oliver-Willwong R; Job S; Zhu L; Lemme F; Hammer AE; Vuong A; Messenheimer JA
    Epilepsia; 2008 Mar; 49(3):410-7. PubMed ID: 17825077
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A review of the metabolic effects of controlled-release Phentermine/Topiramate.
    Kiortsis DN
    Hormones (Athens); 2013; 12(4):507-16. PubMed ID: 24457398
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In brief: topiramate extended-release capsules (Qudexy XR).
    Med Lett Drugs Ther; 2014 Dec; 56(1457):e126. PubMed ID: 25461233
    [No Abstract]   [Full Text] [Related]  

  • 24. Cinema-like sensory phenomena in a migraine patient on topiramate.
    Tandon R; Verma SK
    J Postgrad Med; 2018; 64(1):66-67. PubMed ID: 29386418
    [No Abstract]   [Full Text] [Related]  

  • 25. Levetiracetam extended release for the treatment of patients with partial-onset seizures: A long-term, open-label follow-up study.
    Chung S; Ceja H; Gawłowicz J; McShea C; Schiemann J; Lu S
    Epilepsy Res; 2016 Feb; 120():7-12. PubMed ID: 26716580
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of phentermine and topiramate versus phentermine/topiramate extended-release in obese adults.
    Aronne LJ; Wadden TA; Peterson C; Winslow D; Odeh S; Gadde KM
    Obesity (Silver Spring); 2013 Nov; 21(11):2163-71. PubMed ID: 24136928
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Post-marketing experience with nevirapine extended release (XR) tablets: effectiveness and tolerability in a population-based cohort in British Columbia, Canada.
    Lepik KJ; Yip B; McGovern RA; Ding E; Nohpal A; Watson BE; Toy J; Akagi L; Harrigan PR; Moore DM; Hogg RS; Montaner JS; Barrios R
    Antivir Ther; 2015; 20(7):721-30. PubMed ID: 25960569
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures.
    Ben-Menachem E; Henriksen O; Dam M; Mikkelsen M; Schmidt D; Reid S; Reife R; Kramer L; Pledger G; Karim R
    Epilepsia; 1996 Jun; 37(6):539-43. PubMed ID: 8641230
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and tolerability of topiramate 200 mg/d in the prevention of migraine with/without aura in adults: a randomized, placebo-controlled, double-blind, 12-week pilot study.
    Silberstein SD; Hulihan J; Karim MR; Wu SC; Jordan D; Karvois D; Kamin M
    Clin Ther; 2006 Jul; 28(7):1002-11. PubMed ID: 16990078
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of the effects of quetiapine extended-release and quetiapine immediate-release on cognitive performance, sedation and patient satisfaction in patients with schizophrenia: a randomised, double-blind, crossover study (eXtRa).
    Riedel M; Schmitz M; Østergaard PK; Ferrannini L; Franco MA; Alfano V; Vansvik ED
    Schizophr Res; 2015 Mar; 162(1-3):162-8. PubMed ID: 25592805
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Topiramate versus amitriptyline in migraine prevention: a 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs.
    Dodick DW; Freitag F; Banks J; Saper J; Xiang J; Rupnow M; Biondi D; Greenberg SJ; Hulihan J;
    Clin Ther; 2009 Mar; 31(3):542-59. PubMed ID: 19393844
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment patterns, healthcare resource utilization and costs in patients with bipolar disorder, newly treated with extended release or immediate release quetiapine fumarate using US healthcare administrative claims data.
    Locklear JC; Alemayehu B; Brody RS; Chavoshi S; Tunceli O; Kern D; Earley WR
    Clin Ther; 2013 Dec; 35(12):1923-32. PubMed ID: 24275622
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A naturalistic comparison of amoxicillin/clavulanate extended release versus immediate release in the treatment of acute bacterial sinusitis in adults: A retrospective data analysis.
    Jackson J; Fernandes AW; Nelson W
    Clin Ther; 2006 Sep; 28(9):1462-71. PubMed ID: 17062318
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Once-daily extended-release levetiracetam as adjunctive treatment of partial-onset seizures in patients with epilepsy: a double-blind, randomized, placebo-controlled trial.
    Peltola J; Coetzee C; Jiménez F; Litovchenko T; Ramaratnam S; Zaslavaskiy L; Lu ZS; Sykes DM;
    Epilepsia; 2009 Mar; 50(3):406-14. PubMed ID: 19317886
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of febuxostat extended release and immediate release in patients with gout and moderate renal impairment: phase II placebo-controlled study.
    Gunawardhana L; Becker MA; Whelton A; Hunt B; Castillo M; Saag K
    Arthritis Res Ther; 2018 May; 20(1):99. PubMed ID: 29848361
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tolerability of topiramate in children and adolescents.
    Reith D; Burke C; Appleton DB; Wallace G; Pelekanos J
    J Paediatr Child Health; 2003 Aug; 39(6):416-9. PubMed ID: 12919493
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A pooled analysis of adjunctive topiramate in refractory partial epilepsy.
    Peeters K; Adriaenssen I; Wapenaar R; Neto W; Pledger G
    Acta Neurol Scand; 2003 Jul; 108(1):9-15. PubMed ID: 12807387
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial.
    Silberstein SD; Lipton RB; Dodick DW; Freitag FG; Ramadan N; Mathew N; Brandes JL; Bigal M; Saper J; Ascher S; Jordan DM; Greenberg SJ; Hulihan J;
    Headache; 2007 Feb; 47(2):170-80. PubMed ID: 17300356
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative pharmacokinetic analysis of USL255, a new once-daily extended-release formulation of topiramate.
    Lambrecht LJ; Shekh-Ahmad T; Todd WM; Halvorsen MB; Bialer M
    Epilepsia; 2011 Oct; 52(10):1877-83. PubMed ID: 21770925
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Steady-state pharmacokinetics and bioavailability of immediate-release and extended-release formulations of lamotrigine in elderly epilepsy patients: Use of stable isotope methodology.
    Polepally AR; Remmel RP; Brundage RC; Leppik IE; Rarick JO; Ramsay RE; Birnbaum AK
    J Clin Pharmacol; 2015 Oct; 55(10):1101-8. PubMed ID: 25903807
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.